Simultaneous Estimation of Mometasone Furoate and Salicylic Acid in Topical Formulation By UV-Visible Spectrophotometry
Int J Chem Sci
Introduction Mometasone furoate [MF] (FIG. 1) is chemically 9, 21-dichloro-17α-[(2-furanylcarbonyl) oxy]-11β-hydroxy-16 αmethylpregna-1,4-diene-3,20-dione, a high potency glucocorticoid. It has anti-inflammatory, immunosuppressive, vasoconstriction and antiproliferative actions. It is effective for treatment of skin diseases like eczema, dermatitis and psoriasis. Corticosteroids are thought to act by the induction to phospholipase A2 inhibitory proteins, collectively called lipocortin's. It is
... ipocortin's. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation [1, 2] . It is official in IP, BP and USP    . Abstract A UV-Visible spectrophotometric method was developed for simultaneous estimation of Mometasone furoate and Salicylic acid in topical formulation. Absorbance correction method was used for estimation. Since both drugs are present in vast concentration difference, estimation was done by standard addition technique. Methanol was used as a solvent. From overlain spectra, wavelengths 300 nm and 250 nm were selected for analysis. The % drug content in marketed formulation was found to be 97.54 and 103.85 for Mometasone furoate and Salicylic acid respectively. The developed method was validated as per ICH guidelines. The method was found to be linear in the concentration range of 1-10 μg/ml and 5-50 μg/ml for Mometasone furoate and Salicylic acid respectively. Accuracy of the method was determined by recovery studies. Precision of method was estimated by repeatability and intermediate precision studies. From results of validation parameters, it was found that, the developed method is accurate, precise and specific. Hence, it can be used successfully for routine quality control analysis, for simultaneous estimation of Mometasone furoate and Salicylic acid in topical formulation.